List of Excipients in Branded Drug BUMETANIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	ANHYDROUS LACTOSE
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	CELLULOSE, MICROCRYSTALLINE
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	D&C YELLOW NO. 10
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	FD&C BLUE NO. 1
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	MAGNESIUM STEARATE
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	STARCH, CORN
Edenbridge Pharmaceuticals LLC	BUMETANIDE	bumetanide	42799-119	TALC

Generic Drugs Containing BUMETANIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	bumetanide	0185-0128	ANHYDROUS LACTOSE
Sandoz Inc	bumetanide	0185-0128	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	bumetanide	0185-0128	D&C YELLOW NO. 10
Sandoz Inc	bumetanide	0185-0128	FD&C BLUE NO. 1
Sandoz Inc	bumetanide	0185-0128	FD&C RED NO. 40
Sandoz Inc	bumetanide	0185-0128	MAGNESIUM STEARATE
Sandoz Inc	bumetanide	0185-0128	STARCH, CORN

What are the Most Frequently-Used Excipients in BUMETANIDE?

# Of NDCs	Excipient
3	ALUMINUM OXIDE
18	AMMONIUM ACETATE
48	ANHYDROUS LACTOSE
18	BENZYL ALCOHOL
53	CELLULOSE, MICROCRYSTALLINE
28	D&C YELLOW NO. 10
18	EDETATE DISODIUM

Excipient Strategy and Commercial Opportunities for Bumetanide

Last updated: February 26, 2026

What are the key excipient considerations for Bumetanide formulations?

Bumetanide, a loop diuretic used primarily for edema associated with congestive heart failure, liver, and kidney disease, necessitates specific excipient strategies for stability, bioavailability, and patient compliance.

Common Formulation Types and Excipient Requirements

Bumetanide is available mainly as oral tablets and injectable forms:

• Oral tablets: Require excipients to enhance stability, bioavailability, and convenience.
• Injectable formulations: Need excipients to ensure solubility, sterility, and compatibility.

Typical Excipients in Bumetanide Formulations

Exipient Category	Purpose	Examples
Fillers/Diluents	Bulk formation; facilitate manufacturing	Microcrystalline cellulose, lactose
Disintegrants	Promote tablet breakup for absorption	Cross-linked sodium carboxymethyl cellulose
Binders	Facilitate tablet compression	Povidone, hydroxypropyl cellulose
Lubricants	Prevent sticking during compression	Magnesium stearate
Preservatives & Stabilizers	Extend shelf life	Sodium benzoate, antioxidants

In injectable forms, solubilizers like polyethylene glycol or ethanol may be used. The choice affects stability and administration routes.

Challenges in Excipient Selection

• Bioavailability: As Bumetanide has low oral bioavailability (approximately 80%), excipients influencing dissolution and absorption are critical.
• Stability: The drug's sensitivity to light and moisture necessitates stabilizers and appropriate packaging.
• Patient Compliance: Flavoring agents and easy-to-swallow formulations improve adherence.

What commercial opportunities exist through excipient innovation?

Novel Excipient Use to Enhance Efficacy

• Bioavailability enhancers: Incorporating lipid-based excipients or surfactants could improve absorption.
• Controlled-release matrices: Use of advanced polymers (e.g., ethyl cellulose, polyvinyl acetate) offers extended dosing intervals, reducing pill burden.
• Targeted delivery: Formulations using mucoadhesive polymers could localize delivery in the gastrointestinal tract.

Opportunities in Injectable Formulations

• Stabilizers and solubilizers: Innovation to improve shelf life and ease of preparation.
• Biocompatible excipients: Use of newer, less immunogenic excipients can reduce adverse reactions.

Market and Manufacturing Advantages

• Patents around specific excipient combinations can extend product lifecycle.
• Novel excipient systems may meet regulatory incentives for innovation, driving premium pricing.
• Patient-centric formulations, such as flavor-masked tablets, can expand market share, especially in pediatric and geriatric populations.

Regulatory and Supply Chain Considerations

• High-quality, GMP-compliant excipients are critical.
• Developing proprietary excipient systems can create barriers to generic entry.
• Supply chain reliability and raw material traceability influence manufacturing stability.

How do current patent landscapes influence excipient development?

• Existing patents often cover specific excipient combinations and delivery systems.
• Innovations in biocompatible, bioavailable excipients can carve new IP space.
• Regulatory pathways favoring complex generic formulations could incentivize novel excipient development.

Summary of market players and trends

• Major pharmaceutical excipient manufacturers (e.g., FMC, Roquette, Ashland) are investing in specialized excipients for controlled-release systems.
• Biotech firms exploring sustained-release and targeted delivery systems present potential partners.
• Regulatory agencies increasingly scrutinize excipient safety, urging transparent ingredient sourcing.

Key Takeaways

• Excipient strategy for Bumetanide focuses on enhancing stability, bioavailability, and patient compliance.
• Innovation opportunities include bioavailability enhancers, controlled-release matrices, and targeted delivery systems.
• Patents and regulatory trends shape the landscape, favoring proprietary, high-quality excipient systems.
• Manufacturing reliability and supply chain integrity are vital for commercialization.
• Market differentiation may be achieved through patient-friendly formulations and novel excipient combinations.

FAQs

1. Can new excipient systems extend Bumetanide’s patent protection?
Yes, novel excipient combinations and delivery methods can generate additional IP protection, potentially extending exclusivity.

2. Are there specific excipient challenges unique to Bumetanide?
Yes. Its low oral bioavailability and light/moisture sensitivity require stabilizers and optimized packaging.

3. What regulatory hurdles exist for excipient innovation?
Regulatory agencies require safety and purity data. New excipients must demonstrate that they meet safety standards and do not interact adversely with Bumetanide.

4. How does excipient choice impact dosing frequency?
Controlled-release excipients allow less frequent dosing, which improves adherence and patient outcomes.

5. Who are the key market players supplying Bumetanide excipients?
Major excipient manufacturers include FMC Corporation, Roquette, and Ashland, focusing increasingly on specialized, high-purity ingredients.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.

[2] European Medicines Agency. (2019). Guideline on Pharmaceutical Development and Manufacturing of Parenteral Dosage Forms.

[3] Madu, E. C., & Olayemi, A. B. (2019). Formulation challenges of diuretics. Drug Development and Industrial Pharmacy, 45(5), 789-804.

[4] Li, X., et al. (2021). Advances in controlled-release formulations of diuretics. International Journal of Pharmaceutics, 599, 120399.